Loading insider details...
Beta
Latest Form 4 (Oct 19, 2026): Conversion of 3,294,900 CTY shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 19, 2026 | CITY THERAPEUTICS, INC. (CTY) | Conversion | 3,294,900 | n/a |
| May 4, 2026 | Seaport Therapeutics, Inc. (SPTX) | Conversion | 2,513,686 | n/a |
| Oct 29, 2025 | Neumora Therapeutics, Inc. (NMRA) | Purchase | 1,915,700 | $5.00M |
| Aug 1, 2025 | Prime Medicine, Inc. (PRME) | Purchase | 3,030,300 | $10.00M |
| Jun 10, 2024 | Rapport Therapeutics, Inc. (RAPP) | Conversion | 3,728,738 | n/a |
| Feb 20, 2024 | Prime Medicine, Inc. (PRME) | Purchase | 3,200,000 | $20.00M |
| Dec 13, 2023 | Neumora Therapeutics, Inc. (NMRA) | Other (see footnotes) | 703,061 | n/a |
| Nov 15, 2023 | Neumora Therapeutics, Inc. (NMRA) | Purchase | 31,653 | $371.9K |
| Nov 14, 2023 | Neumora Therapeutics, Inc. (NMRA) | Purchase | 69,127 | $745.2K |
| Nov 7, 2023 | Neumora Therapeutics, Inc. (NMRA) | Purchase | 22,420 | $255.1K |